The Study of Early Stage Osteonecrosis of Femoral Head With Human Umbilical Cord Mesenchymal Stem… (NCT03180463) | Clinical Trial Compass
SuspendedPhase 1/2
The Study of Early Stage Osteonecrosis of Femoral Head With Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ONFH)
Stopped: Others
China30 participantsStarted 2026-12-31
Plain-language summary
The purposes of the study is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cells (hUC-MSC) in treating osteonecrosis of femoral head patients.
Who can participate
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Ficat classification is I, IIa, or IIb period
* no obvious improvement or ingravescence by conservative treatment
* patients or their statutory receive human umbilical cord mesenchymal stem cell of their own will, and signed informed consent form
Exclusion Criteria:
* Ficat classification is third or fourth period
* acute, chronic infection patients
* combined with heart, lung, kidney disease, and cannot tolerate operation
* ankylosing spondylitis patient
* acetabular dysplasia patient
* with tumor
* clinical data deficient
* HIV positive
* pregnancy or breast feeding women
* under other therapy that possibly influence MSC security or efficacy